18F-alfatide PET/CT may predict short-term outcome of concurrent chemoradiotherapy in patients with advanced non-small cell lung cancer

• DOI: 10.1007/s00259-016-3505-3
• Publication Date: 2016-09-07T23:41:28Z
• Authors: Xiaohui Luan; Yong Huang; Song Gao; Xiaorong Sun; Suzhen Wang; Li Ma; Xuepeng Teng; Hong Lu; Jinming Yu; Shuanghu Yuan
• Keywords: Chemoradiotherapy; Standardized uptake value

The study aims to investigate the role of 18F-alfatide positron emission tomography/computed tomography (PET/CT) in predicting short-term outcome concurrent chemoradiotherapy (CCRT) patients with advanced non-small cell lung cancer (NSCLC).Eighteen NSCLC had undergone PET/CT scans before CCRT and parameters including maximum mean standard uptake values (SUVmax/SUVmean), peak (SUVpeak) tumor volume (TVPET TVCT) were obtained. SUVmax normal tissues (lung, blood pool muscle) measured, their ratios denoted as T/NT (T/NTlung, T/NTblood T/NTmuscle). Statistical methods included Two-example t test, Wilcoxon rank-sum Receiver-operating characteristic (ROC) curve analysis logistic regression analyses.We found that SUVmax, SUVpeak, T/NTlung, T/NTmuscle higher non-responders than responders (P = 0.0024, P 0.016, < 0.001, 0.003, 0.004). According ROC analysis, thresholds 5.65, 4.46, 7.11, 5.41, 11.75, respectively. five high sensitivity, specificity accuracy distinguishing responders. Multivariate analyses showed T/NTlung was an independent predictor 0.032).18F-alfatide may be useful NSCLC.